Advent International has outbid KKR in a private equity bidding war for Spectris after the UK industrial group accepted its ...

(Reuters) -British scientific instruments maker Spectris has agreed to private equity firm Advent's sweetened takeover offer ...

Advent International said it increased its takeover bid for precision-measurement company Spectris to 4.2 billion pounds ($5.55 billion).

British scientific instruments maker Spectris has agreed to private equity firm Advent's sweetened takeover bid valued at 4.8 billion pounds ($6.38 billion), including debt, the companies said on ...

Precision instrument maker Spectris has agreed to be bought by Advent International after it trumped an offer from US ...

Advent’s increased offer represents a 2.5 percent increase to the KKR offer. This means the shareholders will receive an additional £1.00 per share, amounting to a total increase of £101.5 million ...

The firm is acting for the Just Group in its £2.4 billion sale, a month after it helped conclude the sale of Spectris to a ...

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease ...

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

- Spectris™ significantly decreased the Alzheimer’s Disease Dependence Score by 56.4% over 18 months, indicating preserved function and reduced caregiver burden - Strong safety profile with no ...

Spectris' Earnings Growth And 10% ROE To begin with, Spectris seems to have a respectable ROE. Even when compared to the industry average of 10% the company's ROE looks quite decent.

Spectris™ is currently being evaluated in HOPE, a pivotal, randomized, sham-controlled trial enrolling 670 patients with mild-to-moderate Alzheimer’s disease.